# Link Cell Therapies

> Logic-gated CAR-T company that added a $30 million extension, increasing its Series A to $90 million.

## Why it is interesting

Clinical dosing and financing expansion happened together; the correct funding interpretation is a $30M extension to a $90M Series A, not a new $90M round.

## Profile

- **Latest funding:** Series A extension — $30M extension; $90M total Series A (September 29, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $30M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Johnson & Johnson Innovation

## Key facts

- Sep 2026: $30M extension increased Series A to $90M
- Company began Phase 1 dosing of LNK001

## Funding history

- Series A extension · $30M extension; $90M total Series A · September 29, 2026
  Source: https://thehealthtechsignal.com/article/link-cell-lnk001-two-marker-car-t

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/link-cell-therapies